Search Result

Results for "

PI3Kγ/δ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (7) Apoptosis (23) ATM/ATR (1) Autophagy (9) c-Myc (1) Caspase (1) CD3 (1) CDK (2) DNA-PK (3) EGFR (1) Epigenetic Reader Domain (2) HDAC (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) Interleukin Related (1) Isotope-Labeled Compounds (2) MEK (1) Mitochondrial Metabolism (1) Mitophagy (7) MMP (1) mTOR (20) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) Paraptosis (1) PARP (1) PD-1/PD-L1 (1) PI3K (83) PI4K (1) PPAR (1) PROTACs (1) Reactive Oxygen Species (ROS) (6) Reference Standards (7) SARS-CoV (1) VEGFR (1)
By Research Areas:	Cancer (76) Infection (2) Inflammation/Immunology (15) Metabolic Disease (4) Neurological Disease (4)

By Targets:

Akt (7)

Apoptosis (23)

ATM/ATR (1)

Autophagy (9)

c-Myc (1)

Caspase (1)

CD3 (1)

CDK (2)

DNA-PK (3)

EGFR (1)

Epigenetic Reader Domain (2)

HDAC (2)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

MEK (1)

Mitochondrial Metabolism (1)

Mitophagy (7)

MMP (1)

mTOR (20)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

Paraptosis (1)

PARP (1)

PD-1/PD-L1 (1)

PI3K (83)

PI4K (1)

PPAR (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (6)

Reference Standards (7)

SARS-CoV (1)

VEGFR (1)

By Research Areas:

Cancer (76)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (4)

Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18085

Quercetin 195+ Cited Publications	Reactive Oxygen Species (ROS) PI3K Autophagy Mitophagy Apoptosis	Cancer
Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-18085A

Quercetin hydrate 195+ Cited Publications	PI3K Autophagy Mitophagy Apoptosis Reactive Oxygen Species (ROS)	Cancer
Quercetin hydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a *PI3K* inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-15346

Copanlisib 30+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and *PI3Kγ*, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 30+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and *PI3Kγ*, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-19962

Paxalisib 5 Publications Verification GDC-0084	PI3K mTOR	Cancer
Paxalisib (GDC-0084) is a brain penetrant inhibitor of *PI3K* and mTOR, with K_is of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively .

HY-13898

Taselisib 20+ Cited Publications GDC-0032; RG-7604	PI3K	Cancer
Taselisib (GDC-0032) is a potent *PI3K* inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-12868

Bimiralisib 4 Publications Verification PQR309	PI3K mTOR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I *PI3K/mTOR* inhibitor with IC₅₀s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, *PI3Kγ* and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor.

HY-13246

Apitolisib 10+ Cited Publications GDC-0980; GNE 390; RG 7422	PI3K mTOR Apoptosis	Cancer
Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC₅₀s of 5 nM/27 nM/7 nM/14 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?K_i?of 17 nM for mTOR**.

HY-N0146

Quercetin dihydrate 190+ Cited Publications	PI3K Apoptosis	Inflammation/Immunology Cancer
Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a *PI3K* inhibitor with *IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K* δ and PI3K β, respectively .**

HY-18085R

Quercetin (Standard)	Reactive Oxygen Species (ROS) Reference Standards PI3K Autophagy Mitophagy Apoptosis	Cancer
Quercetin (Standard) is the analytical standard of Quercetin. This product is intended for research and analytical applications. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-12513

Samotolisib 5+ Cited Publications LY3023414	PI3K DNA-PK mTOR Autophagy	Cancer
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC₅₀s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations .

HY-50847

ZSTK474 15+ Cited Publications	PI3K Autophagy	Cancer
ZSTK474 is an ATP-competitive pan-class I *PI3K* inhibitor with IC₅₀s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.

HY-12330

AZD8186 5+ Cited Publications	PI3K	Cancer
AZD8186 is a *PI3K* inhibitor, which potently inhibits PI3Kβ (IC₅₀=4 nM) and PI3Kδ (IC50₅₀=12 nM) with selectivity over PI3Kα (IC₅₀=35 nM) and PI3Kγ (IC₅₀=675 nM).

HY-16526

Pilaralisib 5 Publications Verification XL-147; SAR245408	PI3K	Cancer
Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC₅₀s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.

HY-10683

PKI-402 10+ Cited Publications	PI3K mTOR	Cancer
PKI-402 is a selective, reversible, ATP-competitive inhibitor of *PI3K, including PI3K-α mutants, and mTOR* (IC₅₀=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-111508

PI3K/mTOR Inhibitor-2 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC₅₀s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR . Antitumor activity .

HY-144806

PI3K/AKT-IN-1 10+ Cited Publications	PI3K Akt Apoptosis	Cancer
PI3K/AKT-IN-1 is an effective *PI3K/AKT* dual inhibitor (IC₅₀ of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis .

HY-17645

Tenalisib 1 Publications Verification RP6530	PI3K	Cancer
Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and *PI3Kγ* inhibitor with IC₅₀ values of 25 and 33 nM, respectively.

HY-13531

AS-604850 1 Publications Verification	PI3K	Cancer
AS-604850 is a potent, selective and ATP-competitive *PI3Kγ* inhibitor with an IC₅₀ value of 0.25 μM and a K_i value of 0.18 μM. AS-604850 shows isoform selective inhibitor of *PI3Kγ* with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively .

HY-13431

KU-0060648 4 Publications Verification	DNA-PK PI3K mTOR	Cancer
KU-0060648 is a dual inhibitor of *PI3K* and DNA-PK with IC₅₀s of 4 nM, 0.5 nM, 0.1 nM, 0.594 nM and 8.6 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and DNA-PK, respectively .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual pan-PI3-kinase/mTOR inhibitor with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-11080

PKI-179 1 Publications Verification	PI3K mTOR	Cancer
PKI-179 is a potent and orally active dual *PI3K/mTOR* inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for *PI3K-α, PI3K-β, PI3K-γ, PI3K-δ* and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo .

HY-13333

NVP-BAG956 BAG 956	PI3K	Cancer
NVP-BAG956 is an ATP-competitive *PI3K* inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-19798

PI4KIIIbeta-IN-9 5 Publications Verification	PI4K PI3K	Cancer
PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC₅₀ of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and *PI3Kγ* with IC₅₀s of 152 nM and 1046 nM, respectively.

HY-18085S1

Quercetin-d3 1 Publications Verification	Isotope-Labeled Compounds PI3K Autophagy Mitophagy Reactive Oxygen Species (ROS) Apoptosis	Cancer
Quercetin-d₃ is the deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-162713

MTX-531	EGFR PI3K PPAR	Cancer
MTX-531 is an oral drug that inhibits EGFR (with an IC₅₀ of 14.7 nM) and *PI3K* (with IC₅₀ values of 6.4, 233, 8.3, and 1.1 nM for PI3Kα, PI3Kβ, *PI3Kγ, and PI3Kδ respectively), and it has anti-tumor effects. MTX-531 also acts as a weak agonist of PPARγ, with an IC₅₀* of 2.5 µM, helping to alleviate hyperglycemia induced by PI3K inhibitors .

HY-112443

AZD3458	PI3K	Metabolic Disease Inflammation/Immunology Cancer
AZD3458 is a potent and remarkably selective *PI3Kγ* inhibitor with pIC₅₀s of 9.1, 5.1, <4.5, and 6.5 for *PI3Kγ, PI3Kα, PI3Kβ, and PI3K*δ, respectively .

HY-115870

AZD8154	PI3K	Inflammation/Immunology
AZD8154 is a selective PI3Kγδ dual inhibitor. AZD8154 can suppress PI3Kγ and PI3Kδ signaling pathway activation. AZD8154 can be used for the researches of inflammation and immunology, such as asthma .

HY-143404

PI3K-IN-30 3 Publications Verification	PI3K	Cancer
PI3K-IN-30 (compound 6d) is a potent *PI3K* inhibitor with IC₅₀s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .

HY-110109

ETP-45658	PI3K DNA-PK mTOR	Cancer
ETP-45658 is a potent *PI3K* inhibitor, with IC₅₀s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for PI3Kα, PI3Kδ, PI3Kβ and *PI3Kγ, respectively. ETP-45658 also can inhibit DNA-PK* (IC₅₀=70.6 nM) and mTOR (IC₅₀=152.0 nM). ETP-45658 can be used for the research of cancer .

HY-153894

SRX3177	CDK Epigenetic Reader Domain PI3K NF-κB SARS-CoV	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SRX3177 is a triple inhibitor of CDK4/6, *PI3K, and BRD4, with IC₅₀s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein* and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer .

HY-174461

PROTAC PI3Kα degrader-1	PROTACs PI3K	Cancer
PROTAC PI3Kα degrader-1 is a PI3Kα PROTAC degrader (DC₅₀ = 0.08 μM), demonstrating good selectivity for PI3Kα degradation over PI3Kβ, PI3Kγ, and PI3Kδ. PROTAC PI3Kα degrader-1 effectively degrades PI3Kα in a time- and concentration-dependent, over PI3Kβ, PI3Ky and PI3Kδ, and potently inhibited the phosphorylation of AKT at the Ser473site. PROTAC PI3Kα degrader-1 shows significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models. (Pink: PI3Kα ligand : (HY-174798), Blue: E3 ligase CRBN Ligand (HY-10984), Black: Linker, E3 ligase ligand-linker conjugate (HY-W940885)) .

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-150618

PI3Kα-IN-9 1 Publications Verification	PI3K Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with IC₅₀ values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively. PI3Kα-IN-9 has antiproliferative activity and induces apoptosis. PI3Kα-IN-9 can be used for cancer research .

HY-10812

GNE-490	PI3K mTOR	Cancer
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model .

HY-128333

PI3K/mTOR Inhibitor-4	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-4 is an orally active pan-class I *PI3K/mTOR* inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC₅₀ values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and *PI3Kγ* dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

HY-18085S2

Quercetin-13C3	Isotope-Labeled Compounds PI3K Autophagy Mitophagy Reactive Oxygen Species (ROS) Apoptosis	Cancer
Quercetin- ¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-118521

AS-041164	PI3K	Inflammation/Immunology
AS-041164 is a potent, selective and orally active *PI3Kγ* isoform inhibitor with an IC₅₀ of 70 nM. AS-041164 shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC₅₀s of 240 nM, 1.45 μM, and 1.70 μM, respectively). AS-041164 has anti-inflammatory effects .

HY-18085S

Quercetin-d5	PI3K Autophagy Mitophagy Apoptosis	Cancer
Quercetin-d₅ is a deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-100694

GS-9901	PI3K	Inflammation/Immunology
GS-9901 is a highly selective and orally active PI3Kδ inhibitor with an IC₅₀ of 1 nM. GS-9901 has ≥100 fold selectivity for PI3Kα (IC₅₀ of 750 nM), PI3Kβ (IC₅₀ of 100 nM) and PI3Kγ (IC₅₀ of 190 nM). GS-9901 can be used for the study of rheumatoid arthritis .

HY-N0146R

Quercetin dihydrate (Standard)	Reference Standards PI3K Apoptosis	Inflammation/Immunology Cancer
Quercetin (dihydrate) (Standard) is the analytical standard of Quercetin (dihydrate). This product is intended for research and analytical applications. Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC₅₀s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, *PI3Kγ, PI3Kδ and mTOR*, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-143403

PI3K-IN-31	PI3K	Cancer
PI3K-IN-31 (Compound 6b) is a potent *PI3K* inhibitor with IC₅₀s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, *PI3Kγ, and PI3K*δ, respectively. PI3K-IN-31 has anticancer effects .

HY-112614

ATM Inhibitor-1	ATM/ATR	Cancer
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC₅₀ of 0.7 nM, shows weak activity against mTOR (IC₅₀, 21 μM), DNAPK (IC₅₀, 2.8 μM), PI3Kα (IC₅₀, 3.8 μM), PI3Kβ (IC₅₀, 10.3 μM), PI3Kγ (IC₅₀, 3 μM) and PI3Kδ (IC₅₀, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity .

HY-131345A

(S)-PI3Kα-IN-4	PI3K	Cancer
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC₅₀ of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and *PI3Kγ, respectively. (S)-PI3K*α-IN-4 can be used for the research of cancer .

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent *PARP/PI3K* inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .

HY-112608

CHMFL-PI3KD-317	PI3K	Cancer
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC₅₀, 62.6 nM), PI3Kβ (IC₅₀, 284 nM), PI3Kγ (IC₅₀, 202.7 nM), PIK3C2A (IC₅₀, >10000 nM), PIK3C2B (IC₅₀, 882.3 nM), VPS34 (IC₅₀, 1801.7 nM), PI4KIIIA (IC₅₀, 574.1 nM) and PI4KIIIB (IC₅₀, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC₅₀ of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells .

HY-130133

DHW-221	PI3K mTOR Akt Apoptosis Paraptosis p38 MAPK Mitochondrial Metabolism P-glycoprotein CDK MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
DHW-221 is a potent orally active dual *PI3K/mTOR* inhibitor, exhibiting low nanomolar potency against all four Class I PI3K isoforms and mTOR (PI3Kα, IC₅₀ = 0.50 nM; PI3Kβ, IC₅₀ = 1.9 nM; PI3Kγ, IC₅₀ = 1.8 nM; PI3Kδ, IC₅₀ = 0.74 nM; mTOR, IC₅₀ = 3.9 nM). DHW-221 exerts antitumor effects by blocking the *PI3K/Akt/mTOR* pathway and inducing mitochondrial apoptosis and paraptosis (via Endoplasmic Reticulum (ER) stress and MAPK signaling) and arrests cell cycle, thereby inhibiting cell migration, invasion and angiogenesis. DHW-221 inhibits tumor growth in both the A549/Taxol (HY-B0015) and the HCC827 xenograft mouse models. DHW-221 can be used for non-small cell lung cancer (NSCLC), colon and breast cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure